Market Cap (In USD)
65.65 Million
Revenue (In USD)
173.85 Million
Net Income (In USD)
-767.99 Million
Avg. Volume
491.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.1446-0.35
- PE
- -0.77
- EPS
- -0.21
- Beta Value
- 2.127
- ISIN
- KYG5210T1040
- CUSIP
- -
- CIK
- -
- Shares
- 405271891.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Min Liu
- Employee Count
- -
- Website
- https://www.jwtherapeutics.com
- Ipo Date
- 2021-07-15
- Details
- JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
More Stocks
-
GS-PD
-
AMICAmic Forging Limited
AMIC
-
BYSDBayside Corporation
BYSD
-
2263
-
0975
-
PUCCF
-
2488
-
PDNLA